Dexcom shares plunge after cautious 2026 outlook, despite strong Q3 results, as analysts cite margin pressure and uncertainty around G7 sensor uptake and accuracy.
Investor Tom Hulick highlights Broadcom's AI-focused, power-efficient ASICs and Eli Lilly's GLP-1 drug pipeline, while StockStory cautions against uncritical acceptance of Wall Street price targets.
Dexcom shares plunge after cautious 2026 outlook, despite strong Q3 results, as analysts cite margin pressure and uncertainty around G7 sensor uptake and accuracy.
Investor Tom Hulick highlights Broadcom's AI-focused, power-efficient ASICs and Eli Lilly's GLP-1 drug pipeline, while StockStory cautions against uncritical acceptance of Wall Street price targets.